SEOUL, South Korea & AHMEDABAD, India & ENGLEWOOD CLIFFS, N.J.--(BUSINESS WIRE)--Enzychem Lifesciences (KOSDAQ: 183490) and Cadila Healthcare Ltd, a part of the Zydus Group, today announced that they ...

STOCKHOLM, SWEDEN – February 8, 2013. Pergamum AB and Cadila Pharmaceuticals Ltd today announced a strategic collaboration to develop a novel treatment of infections with a unique targeting mechanism ...

Biological E. COVID shot gets India emergency approval for 12-18 age group Indian vaccine maker Biological E. Ltd said on Monday its COVID-19 vaccine received an emergency use approval in the country ...

MUMBAI (Reuters) - India's Cadila Healthcare Ltd has received a U.S. Food and Drug Administration (FDA) warning letter for violating manufacturing standards at two of its production facilities, the ...

Shire Files Suit against Cadila Healthcare Limited doing business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc. Dublin, Ireland and Philadelphia, US - July 8, 2010 - Shire plc (LSE: SHP, ...

Cadila Healthcare on Monday said its subsidiary has inked a pact with Integrace Pvt Ltd to sell two brands -- Mifegest and Cytolog. Zydus Healthcare Ltd, a wholly-owned subsidiary of the company, has ...

India’s Cadila Healthcare Ltd. has sought approval from the local drug regulator for its DNA-based vaccine against Covid-19 after the shot proved effective in clinical trials. The drugmaker applied ...

Given the publicity that has come with FDA bans on a growing list of Indian facilities, even a report of an FDA shortfall at a plant can have consequences these days. That is where India's Cadila ...

More money is being spent on medical R&D than ever before, but with few new drugs to show for it. The race is on to find technological solutions that will speed up drug development and deliver better ...

Cadila Healthcare Ltd. (also known as Zydus Cadila) has received emergency use authorization (EUA) in India for Zycov-D, making it the world’s first plasmid DNA vaccine for COVID-19. Besides the adult ...

There was no slowing of biopharma innovation in 2021, even as industry directed significant resources to, while feeling the impact of, the ongoing COVID-19 pandemic. The year saw big wins for ...